Trial Profile
KRP-AM1977Y Phase II Clinical Study-To assess efficacy, safety and pharmacokinetics of KRP-AM1977Y in the patients with community acquired pneumonia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Lascufloxacin (Primary)
- Indications Community-acquired pneumonia
- Focus Therapeutic Use
- Sponsors Kyorin Pharmaceutical
- 25 Apr 2017 Results assessing the efficacy, safety, and pharmacokinetics of lascufloxacin intravenous infusion in patients with community acquired pneumonia, at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
- 01 Aug 2016 Status changed from active, no longer recruiting to completed.
- 14 Mar 2016 New trial record